Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+primary resistant or relapsed acute myeloid leukemia

被引：58

作者：

Tsimberidou, A ^{[1
]}

Cortes, J ^{[1
]}

Thomas, D ^{[1
]}

Garcia-Manero, G ^{[1
]}

Verstovsek, S ^{[1
]}

Faderl, S ^{[1
]}

Albitar, M ^{[1
]}

Kantarjian, H ^{[1
]}

Estey, E ^{[1
]}

Giles, FJ ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

LEUKEMIA RESEARCH | 2003年 / 27卷 / 10期

关键词：

Mylotarg (TM); fludarabine; cytarabine; cyclosporine; gemtuzumab ozogamicin; acute myelogenous leukemia; refractory;

D O I：

10.1016/S0145-2126(03)00022-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical resistance to gemtuzumab ozogamicin (Mylotarg(TM)) in acute myeloid leukemia (AML) is associated with blast multidrug resistance (MDR) phenotype. A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Nine (28%) patients obtained complete remission (CR), two (6%) CR with incomplete platelet recovery. Overall median survival was 5.3 months, 12-month survival rate 19%. Fourteen patients (44%) developed grade 3/4 hyperbilirubinemia; six (18%) grade 3/4 hepatic transaminitis; three (9%) hepatic veno-occlusive disease (VOD). CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：893 / 897

页数：5

共 28 条

[21] Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg®) [J].

McDonald, GB .

CLINICAL LYMPHOMA, 2002, 2 :S35-S39

[22] Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate [J].

Neumeister, P ;

Eibl, M ;

Zinke-Cerwenka, W ;

Scarpatetti, M ;

Sill, H ;

Linkesch, W .

ANNALS OF HEMATOLOGY, 2001, 80 (02) :119-120

[23] Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotug) therapy [J].

Rajvanshi, P ;

Shulman, HM ;

Sievers, EL ;

McDonald, GB .

BLOOD, 2002, 99 (07) :2310-2314

[24] Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse [J].

Sievers, EL ;

Larson, RA ;

Stadtmauer, EA ;

Estey, E ;

Löwenberg, B ;

Dombret, H ;

Karanes, C ;

Theobald, M ;

Bennett, JM ;

Sherman, ML ;

Berger, MS ;

Eten, CB ;

Loken, MR ;

van Dongen, JJM ;

Bernstein, ID ;

Appelbaum, FR .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3244-3254

[25]

Sievers EL, 2000, BLOOD, V96, p206B

[26]

Stadtmauer E, 2001, BLOOD, V98, p124A

[27]

TSIMBERIDOU A, IN PRESS CANCER

[28] PROOF WITHOUT PREJUDICE - USE OF KOLMOGOROV-SMIRNOV TEST FOR ANALYSIS OF HISTOGRAMS FROM FLOW SYSTEMS AND OTHER SOURCES [J].

YOUNG, IT .

JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1977, 25 (07) :935-941

← 1 2 3 →